Familial Alzheimer’s disease is a rare, inherited form of Alzheimer’s caused by specific gene mutations that are passed directly from parent to child. Unlike the common form of Alzheimer’s, which typically appears after age 65 and involves a mix of genetic and environmental factors, familial Alzheimer’s is driven by a single mutation that virtually guarantees the carrier will develop the disease, often decades earlier. Symptoms can begin as early as a person’s 30s or 40s, and almost always appear before age 65.
How It Differs From Common Alzheimer’s
Most Alzheimer’s cases are “sporadic,” meaning they arise from a combination of age, genetics, lifestyle, and factors researchers still don’t fully understand. Familial Alzheimer’s is fundamentally different. It follows an autosomal dominant inheritance pattern, which means only one copy of the mutated gene is needed to cause the disease. If one of your parents carries the mutation, you have a 50% chance of inheriting it. And if you do inherit it, the mutation is considered nearly 100% penetrant: you will almost certainly develop Alzheimer’s.
You may have heard of the APOE4 gene variant and its connection to Alzheimer’s risk. That’s a different situation entirely. APOE4 is a susceptibility gene. It increases your odds of developing late-onset Alzheimer’s, but having it doesn’t mean you’ll get the disease, and not having it doesn’t mean you’re safe. The mutations behind familial Alzheimer’s are deterministic. They don’t raise your risk; they set the disease in motion.
The Three Genes Involved
Three genes have been identified as causes of familial Alzheimer’s: APP, PSEN1, and PSEN2. Each one plays a role in how the brain produces and processes a protein fragment called amyloid-beta, the primary ingredient in the sticky plaques that build up in Alzheimer’s brains.
The APP gene provides the blueprint for a larger protein that gets cut into smaller pieces during normal brain activity. One of those fragments is amyloid-beta. Mutations in APP cause the brain to produce abnormal amounts of this fragment or a particularly toxic version of it. PSEN1 and PSEN2 encode parts of the molecular “scissors” (an enzyme called gamma-secretase) that do the cutting. When either gene is mutated, the scissors work differently, producing more of the harmful amyloid-beta fragments or shifting the ratio toward a stickier, more plaque-prone form.
Of the three, PSEN1 mutations are the most common cause of familial Alzheimer’s and tend to produce the earliest symptoms, sometimes in a person’s 30s. PSEN2 mutations are the rarest and can have a slightly later and more variable onset. APP mutations fall somewhere in between. Regardless of which gene is involved, the end result is the same: amyloid plaques accumulate in the brain, triggering a cascade of damage that eventually leads to dementia.
When Symptoms Start
The hallmark of familial Alzheimer’s is early onset. Carriers typically develop symptoms between their 30s and 50s, though the exact age depends partly on which gene is mutated and even which specific mutation within that gene a person carries. Within a given family, the age of onset tends to be relatively consistent across generations, which can give affected families a rough sense of when symptoms might appear.
What makes this especially difficult is the long silent phase before any symptoms show up. Brain changes begin years before a person notices cognitive problems. Amyloid-beta starts accumulating in the brain up to 15 years before the first symptoms emerge. During that time, the brain is already changing, but the person feels and functions normally.
Symptoms That Set It Apart
The core symptoms of familial Alzheimer’s overlap with the common form: progressive memory loss, confusion, difficulty with planning and problem-solving, and eventually the loss of ability to manage daily life. But research comparing familial cases (particularly those with PSEN1 mutations) to non-familial early-onset cases has found some distinguishing features.
People with familial Alzheimer’s are significantly more likely to experience myoclonus, which involves sudden, involuntary muscle jerks. In one study, about 41% of familial patients had a history of myoclonus compared to just 2.5% of non-familial early-onset patients. Gait abnormalities, persistent headaches, and pseudobulbar affect (episodes of uncontrollable laughing or crying that don’t match the person’s actual mood) were also more common in the familial group. These features, especially when combined with a young age of onset and progressive decline, can be clues that a genetic cause is at play.
Genetic Testing and Counseling
Genetic testing can confirm whether someone carries one of the three familial Alzheimer’s mutations. But the decision to get tested is deeply personal and carries significant emotional weight, particularly for people who are still healthy and may be decades away from symptoms. Professional guidelines are clear that testing should only happen alongside genetic counseling with someone who has expertise in this area. Direct-to-consumer genetic tests are not recommended for this purpose.
Testing is generally offered in three situations: when a person already showing early-onset symptoms has a family history of dementia (or an unknown family history, such as in cases of adoption), when a family shows an autosomal dominant pattern of dementia with at least one early-onset case, or when a relative has already been confirmed to carry a known mutation. Testing children is not recommended. For adults who have no symptoms but want to know their status, the process follows a structured protocol similar to the one used for Huntington’s disease, with multiple counseling sessions before and after the test.
The counseling process involves building a detailed family tree going back at least three generations, noting the age symptoms appeared in each affected relative, the type of dementia diagnosed, and how the diagnosis was made. This pedigree analysis helps determine whether the pattern in a family is consistent with autosomal dominant inheritance or something else entirely.
What Happens in the Brain
The disease process in familial Alzheimer’s follows the same general path as sporadic Alzheimer’s, but it’s set in motion earlier and with more certainty. The mutated genes cause the brain to overproduce amyloid-beta or to produce a version of it that clumps together more readily. These clumps form plaques between brain cells, disrupting communication. Over time, another protein called tau begins to form tangles inside neurons, brain cells die, and entire brain regions shrink. Memory, reasoning, language, and eventually basic bodily functions are all affected as the disease progresses.
Because the genetic cause is known and the timeline is somewhat predictable, familial Alzheimer’s has become an important window into understanding how Alzheimer’s develops in general. The Dominantly Inherited Alzheimer Network, an international research study, tracks mutation carriers and non-carriers from affected families over time. Participants undergo brain imaging, provide blood and spinal fluid samples, and complete cognitive testing. Researchers measure amyloid levels, changes in brain size, and brain metabolism, comparing carriers who have developed symptoms with those who haven’t yet. The goal is to map the biological sequence of Alzheimer’s from its earliest invisible stages through full-blown dementia, knowledge that could eventually improve early diagnosis and treatment for all forms of the disease.
Living With the Risk
For families affected by familial Alzheimer’s, the disease shapes life in ways that go beyond the medical. A 35-year-old who watched a parent decline at 45 faces questions most people never confront at that age: whether to get tested, how to plan financially, whether and when to tell children about the family history. The 50/50 odds of inheritance mean that some siblings in a family will carry the mutation and others won’t, which can create complicated dynamics around guilt, grief, and survivor’s feelings.
Knowing the mutation is present does allow for planning that wouldn’t otherwise be possible. Some carriers use the information to make decisions about long-term care, legal and financial arrangements, and family planning. Preimplantation genetic testing during in vitro fertilization, for example, can identify embryos that do not carry the mutation, giving carriers the option of having children who won’t face the same risk.